Back to search

Peptide record

TPDB92598

IDP-Lb04 Anticancer standard
16 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92598
IDP-Lb04
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 16-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
Chemical: -(CH2)6-CH=CH-(CH2)3 Chemical: a biradical linker links P(4) and K(11)
Sequence
SKAPKVVILSKALEYL
Physicochemical Analysis
C83H143N19O22
RNDCQGHMFTW
LK
1759.16
10.06
3
1
9
+2
2.57
0.513
146.25
Mammalian: 1.9 hour Yeast: >20 hour E.coli: >10 hour
1490
84.70
3
Residue Composition
number
2
A
0
R
0
N
0
D
0
C
1
E
0
Q
0
G
0
H
1
I
3
L
3
K
0
M
0
F
1
P
2
S
0
T
0
W
1
Y
2
V
Amino Acid Distribution
A: 2 R: 0 N: 0 D: 0 C: 0 E: 1 Q: 0 G: 0 H: 0 I: 1 L: 3 K: 3 M: 0 F: 0 P: 1 S: 2 T: 0 W: 0 Y: 1 V: 2
Chemical Descriptors
16
C83H143N19O22
1759.16
10.06
+2
2.57
0.513
Free
-(CH2)6-CH=CH-(CH2)3 a biradical linker links P(4) and K(11)
L
Linear
Free
Anticancer
Synthetic
Evidence Records 3 records
Evidence 1 Activity

Activity

EC50
EC50 > 30 µM
Anticancer
30 µM

Target

Lung Cancer
NCl-H187
Lung

Assay & Model

MTT/Alamamar-Blue/Hexosaminidase activity test
48-72 h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
US20200239547A1

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

EC50
EC50 ~ 12.5 µM
Anticancer
12.5 µM

Target

Lung Cancer
NCl-H82
Lung

Assay & Model

MTT/Alamamar-Blue/Hexosaminidase activity test
48-72 h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
US20200239547A1
Evidence 3 Activity

Activity

EC50
EC50 > 30 µM
Anticancer
30 µM

Target

Lung Cancer
NCl-H510A
Lung

Assay & Model

MTT/Alamamar-Blue/Hexosaminidase activity test
48-72 h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
US20200239547A1